Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-04-30 03:18:12 Source:opinionsViews（143）
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous：Spanish city of Barcelona celebrates day of books and love
Next：Insider Q&A: Avelo Airlines CEO Andrew Levy describes the challenges of starting a new carrier
You may also like
- Who is Humza Yousaf's wife Nadia El
- China intensifies efforts for cease
- Foreign experts hail China's democracy path
- Policies yield key results in Xiong'an
- Scarred UNESCO World Heritage site Jiuzhaigou recovers after quake
- HK chief vows to boost national security education, economy
- Xi calls for closer ties with Vietnam
- China strongly condemns provocative visit of UK politicians to the island of Taiwan
- Ecuador announces complaint against Mexico at top UN court in diplomatic spat